Limonin, an AMPK Activator, Inhibits Hepatic Lipid Accumulation in High Fat Diet Fed Mice
Wang Si-wei, Lan Tian, Chen Hang-fei, Sheng Hao, Xu Chun-yi, Xu Li-feng, Zheng Fang, Zhang Feng
Journal：Frontiers in Pharmacology
IF：5.99
DOI：10.3389/fphar.2022.833705
PMID：35140621
Published：2022-01-24
research field：酶生物化学真菌学食品科学生物技术微生物遗传学
Abstract
NAFLD is the most prevalent liver disease in human history. The treatment is still limited yet. In the current study, we reported that limonin inhibited hepatic lipid accumulation and fatty acid synthesis in HFD fed mice. Using AMPK inhibitor and AMPK deficient C. elegans, we revealed the effect was dependent on the activation of AMPK. We found that limonin activated AMPK through inhibition of cellular energy metabolism and increasing ADP:ATP ratio. Furthermore, the treatment of limonin induced AMPK mediated suppression of the transcriptional activity of SREBP1/2. Our study suggests that limonin may a promising therapeutic agent for the treatment of NAFLD.
本文使用的Yeasen产品
